A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. by Schrape, S. et al.
Br. J. Cancer (1987), 55, 283 286
© The Macmillan Press Ltd., 1987
A comparison of three methods for the determination of the growth
fraction in non-Hodgkin's lymphoma
S. Schrape, D.B. Jones & D.H. Wright
University Pathology, Level E, South Block, General Hospital, Southampton S09 4XY, UK.
Summary The proliferation rate of non-Hodgkin's lymphomas (NHL) was estimated by using 3 different
methods. In cell suspension we determined the proportion of cells in cycle with the monoclonal antibody
(Mab) Ki-67 and also in S-phase after the incorporation of bromo-deoxyruridine (BrdU) utilizing Mab anti-
BrdU. In low grade lymphomas 3.5 + 1.6% of the cells were in cycle and 1.2 +0.9% in S-phase, the
corresponding values for high grade lymphomas were 22.5 + 18.7% and 8.9+7.8% respectively.
Frozen sections of NHL were reacted with an antibody to the transferrin receptor (TR) and Ki67 as
markers for proliferative activity. A high number of TR positive cells was found in low grade lymphomas of
all histological types, whereas Ki67 positivity correlated closely with grading. With a few exceptions, low
grade lymphomas contained less than 25% Ki67 positive cells within the tumour cell population. This
observation is relevant to treatment strategies for low grade NHL.
Schemes for the histological classification of non-Hodgkin's
lymphoma (NHL) are used to determine treatment strategies
and to predict prognosis (Rosenberg et al., 1982). Recently,
methods have been used to determine the proliferation rate
in NHL, based on the measurement of transferrin receptor
(TR) status (Habeshaw et al., 1983) thymidine uptake
(Kvaloy et al., 1985; Costa et al., 1981a) or the
determination of cells in S-phase by flow cytometry (Roos et
al., 1985). The proliferating fraction in NHL may give
additional valuable information relevant to therapy and
prognosis.
In this study we have compared various methods for the
investigation of cells in cycle in NHL. TR status on frozen
section has been compared with the monoclonal cell cycle
marker Ki67 (Gerdes et al., 1984a,b) and on cell suspensions
derived from biopsy material staining with Ki67 has been
undertaken in parallel with the determination of S-phase
using BrdU pre-incubation followed by staining with
monoclonal anti-BrdU. We conclude that staining with Ki67
provides a convenient and reproducible method for cell cycle
analysis which is easily included in routine monoclonal
diagnostic profiles.
Materials and methods
Specimens
Sixty fresh lymph node (LN) biopsies were obtained from
the Southampton and South West Hampshire Health
District. Fifty-four were subsequently diagnoses as NHL and
6 showed reactive changes only. The mean age of the
patients with NHL was 60 years in both sexes, though males
were twice as common as females in this group.
One part of the biopsy was snap frozen in liquid nitrogen
and stored at - 198°C until required for immunohistologic
phenotyping. A second part was fixed in formalin and
processed for conventional hi'stologic examination. Histo-
logical type was assessed on this material and confirmed by
immunostaining of frozen sections with an appropriate panel
of monoclonal antibodies (Jones et al., 1986).
Preparation ofcell suspensions
Where sufficient tissue was available (24 biopsies) cell
suspensions were prepared by passing the material through
wire mesh and suspending the cells in Hank's balanced salt
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solution (HBSS). To separate the mononuclear cells (MNC)
the lymph node was centrifuged through Ficoll/Triosil at
400g for 35min. The interface layer of MNC was washed
twice in HBSS (300g for 10min) before resuspending in
medium RPMI 1640 containing 10% foetal calf serum. The
viability of mononuclear cell suspensions obtained by this
method was always -90% when tested by trypan blue exclu-
sion. The cell count was adjusted to 1 x 106 cellsml 1 and the
cell suspensions then pre-incubated at 37C, in 5% CO2 in air
for 30-60min. After the pre-incubation bromo-deoxyuridine
(BrdU, Sigma) was added to a final concentration of
1-0 M for 60min. After this incubation, proliferation was
stopped by a single wash with ice-cold PBS. The pellet
was resuspended in PBS and cytocentrifuge preparations
were prepared. These slides were air dried for 2-18h and
stored wrapped in aluminium foil at -20°C until stained.
Antibodies and staining methods
Ki67 The Mab Ki-67 was kindly donated by Dr J. Gerdes,
West Berlin. This Mab was raised against the crude nuclear
fraction of L428 cells (Gerdes et al., 1983) and is directed
against a spindle associated protein. Peroxidase-conjugated
anti-mouse Ig was obtained from Dako (Copenhagen,
Denmark).
HB21 Cells producing this Mab were obtained from the
American Type Culture Collection (Clone 5E9; Haynes et
al., 1981). The glycoprotein identified by this antibody has
been shown to be the transferrin receptor (TR; Trowbridge
& Omary, 1981; Sutherland et al., 1981).
Anti-BrdU The incorporated BrdU was detected with
monoclonal anti-BrdU (Becton Dickinson, England). The
slides were fixed in 70% ethanol for 2h at 4°C and air dried.
The DNA was denatured by immersion for 2min in 0.07N
NaOH, followed by the neutralisation of the base in 0.1 M
borate buffer pH 8.5. Anti-BrdU (Grazner, 1982) was then
applied for 30 min and visualised using the enhanced
APAAP method (Cordell et al., 1984) with fast red as
substrate.
Determination ofthe proliferation rate
On frozen sections the percentage of Ki67 and HB21 positive
cells was determined at x 250 magnification by counting
300-600 cells in an area with a characteristic infiltration of
tumour cells. For cell suspensions, an equal number of cells
were counted on cytopreps to determine the percentage of
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cells in cycle (Ki67) and on parallel slides in S-phase (anti-
BrdU). Incubation for 1 h in BrdU allows for the
comparison of the relative proliferation rates of cell samples
derived from different biopsies, but will not necessarily give
the absolute number of cells in S-phase.
Clinical data
Biopsies investigated in this study have been received since
1984. Patient follow-up has, therefore, been relatively short.
Data are presented where definitive information on the
clinical course is available.
Results
Cell suspensions
In 24 cases (21 NHL, 3 reactive LN) we prepared cell
suspensions and determined in parallel the percentages of
Ki67 and anti-BrdU positive cells after 60min incubation.
The results of the study are shown in Figure 1. The widest
range was found within the subgroup of FCC. FCC with
follicular growth pattern contained fewer dividing cells than
FCC with a diffuse pattern. The case (identified as x in
Figures 1 and 2), diagnosed as FCC cb/cc diffuse
(centroblast predominant) showed the highest percentage of
proliferating cells (Ki67 35.5%, anti-BrdU 11.4%). Cell
suspensions of reactive LN often contained as many
proliferating cells as FCC.
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Figure 3 Nuclear staining with the antibody Ki67 of frozen
sections of NHL with high (a) and low (b) proliferation rates.
(Peroxidase x 800).
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Figure I Fractions of cells in cycle ( Ki67 positive) and cells
in S-phase (O anti-BrdU positive) in cell suspensions of NHL.
foll =follicular growth pattern; diff=diffuse growth pattern;
r=biopsy taken in relapse; x =exceptional case, for further
description see text.
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Figure 2 Fractions of Ki67 positive cells on frozen sections.
Capital letters correspond to the clinical data described in the
results. (0) first biopsy: (Q) biopsy at relapse. Vertical lines
mark the medians of each type of NHL.
Frozen sections (Figure 3a, b)
In frozen sections of reactive lymph node Ki67 positive cells
were generally present in germinal follicles. The proportion
of Ki67 positive cells in reactive germinal centres varied
greatly from 10% to 80% of the follicle centre cells.
The percentages of Ki67 positive cells enumerated in
frozen sections of NHL was higher than that determined in
cell suspension as we counted only in areas with a clear
infiltration of tumour cells, whereas the suspension
contained large numbers of reactive cells. B- and T-cell
lymphocytic lymphomas gave a range of Ki67 positivity
from 0 to 15%. In FCC cb/cc with a follicular growth
pattern we found 3 of 9 biopsies exhibited a proportion of
cells in cycle equivalent to that seen in high grade
lymphomas. Five out of 11 cb/cc lymphomas with a diffuse
growth pattern contained more than 25% proliferating cells.
Ki67 positivity of centrocytic lymphomas varied widely from
less than 1% to 45%. Centroblastic lymphomas significantly
showed a wide range of reactivity from 26% to 80% as did
other high grade lymphomas.
The quantification of surface staining with HB21 was less
accurate as it was difficult to distinguish between adjacent
positive and negative cells. Further macrophages in sections
were frequently TR positive. The results of 48 frozen
sections are illustrated in Table I.
Clinical data
The clinical data are summarized in Table II.
Discussion
Our results have demonstrated that the sensitivity of the
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Table I Percentages of HB21 positive cells in frozen
sections of NHL biopsies
NHL n median range
lymphocytic B 7 90 20-90
lymphocytic T/T-zone 3 20 5-30
myeloma 1 25
FCC cb/cc follicular 7 40 1-90
FCC cb/cc diffuse 11 50 1-90
FCC cc 3 70 1-80
FCC cb foll. +diff. 1 95
FCC cb diffuse 5 90 40-90
lymphoblastic T 3 95 95
other high grade lymphomas 4 90 90
reactive germinal centres 3 90 90
three methods chosen for estimating cell proliferation rate
differed. The distinction between low grade and high grade
lymphomas was not as striking in cell suspension as on
frozen sections. With the exception of the case identified as x
in Figures 1 and 2 (low grade lymphoma with extremely high
proliferating rate) the mean value for percentage nuclear
positive cells in low grade lymphoma was 3.5 + 1.6% for
Ki67, whilst 1.2+0.9% of the cells were in S-phase. The
corresponding values in high grade lymphomas were
22.5+18.7% and 8.9+7.8%, respectively. Similar results
were reported from cell suspension studies using FACS
analysis (Costa et al., 1981b; Diamond et al., 1982; Porwit-
Ksiazek et al., 1983; Shackney et al., 1984; Srigley et al.,
1985; Camplejohn & Macartney, 1985) and autoradiography
(Costa et al., 1981a,b).
In cell suspension studies, it is difficult to determine
whether the proliferating cells identified belong to the
tumour cell population or not. Particularly in B cell
lymphomas, where non-neoplastic T cells are numerous
(Arnold et al., 1983; Wright, 1986) and the value obtained
will underestimate the proliferating fraction of the tumour
cells as well as masking differences in individual cases.
Further, tumour cells may be lost during the preparation of
the cell suspension. In contrast, in T cell lymphomas, the
percentage of Ki67 positive cells was almost identical in cell
suspensions and on frozen sections (Figures 1 and 2).
The parallel quantification of the relative proportions of
cells in S-phase (S) and cells in cycle (C) enabled the
calculation of the ratio S/C as an estimate of the relative
proportions of cycling cells in S-phase for individual
biopsies. In low grade lymphomas the mean ratio was 0.25
and in high grade lymphomas 0.37, a significant difference at
the level of 5% (revealed by the 2-tailed Mann-Whitney
test). We propose that the GI-phase in low grade
lymphomas is longer than that in high grade lymphomas.
On frozen sections we used two different Mabs, Ki67 and
HB21 to identify proliferating cells. The transferrin receptor
has been found to be expressed on activated lymphocytes
(Trowbridge & Omary, 1981; Sutherland et al., 1981) and is
also present on, or in, other cell types including
macrophages, histiocytes, dendritic reticulum cells and
hepatocytes (Gerdes et al., 1984a). We detected a high
proportion of HB21 positive cells in lymphocytic lymphomas
(Table I) which contained only small numbers of cells in
cycle and in S-phase. Therefore, we concluded that HB21 is
not a reliable marker for proliferating cells in frozen section.
Other studies report a close correlation between TR
expression, 3H-thymidine uptake (Kvaloy et al., 1984),
Table II Clinical data from selected patients in this study correlated with available figures for Ki67 positivity in frozen section
NHL
(capital letters Age at Stage % Ki67 Died/alive
refer to Istpresentationl bone marrow positive (months) after
Figure 2) sex extranodal cells Treatment (months) Response 1st presentation
myeloma 46/m III ND RT+melph.+pred. (9) stable PR (7)
ND RT progression
ND RT RT
ND RT+melph.+pred. (6) stable
25 RT progression (2) died (26)
FCC cb/cc foll
A 31/m IVA, BM+ve 12.5 RT+pred. (5) stable-progr.
Ar 5 RT+CB (6) stable alive (17)
B 36/m IIAE, stomach 20 RT (2) CR alive (20)
C 66/m IAE, extradural ND RT (2) CR (27)
II 17.5 RT+CHOP/PEPA (4) PR
RT+CB (3) CR alive (45)
D 39/f IIIA 30 CB (2), CB+pred. (2), none
CHOP (6), CHOP+bleo
+MTX (3) none died (16)
FOC cb/cc diff.
A 39/m III/IVA 5 CB low dose (1), CHOP (6)
+local RT good alive (15)
B 43/f IIIA ND watch policy (60)
BM +ve 7.5 CHOP/PEPA +RT
+it MTX CR alive (72)
C 68/m IIA 15 RT+CB (10) CR (9)-relapse
ND CB alive (20)
D 74/m IIAE, kidney 15 CHOP/PEPA (3) CR (5)-relapse
RT+CB (2) stable alive (15)
E 67/m IAE, testis 50 excision relapse after (10)
OAP+ RT progression alive (15)
ND=not done, +ve=positive, RT=radiotherapy, melph.=melphalan; CB=chlorambucil, bleo=bleomycin, it MTX=intrathecal
methotrexate, pred. =prednisolone; CHOP =cyclophosphamide, adriamycin, vincristine, prednisolone; PEPA =procarbazine, etoposide,
prednisolone, adriamycin; OAP=adriamycin, etoposide, chlorambucil.286 S. SCHRAPE et al.
histological grade and clinical outcome (Habeshaw et al.,
1983). However, both these studies employed cell suspensions
and FACS analysis, and, therefore, the results were not
confused by interference of TR in, or on, non-lymphoid cells
in sections. Comparing our results for Ki67 in frozen section
with the recent study by Gerdes et al., (1984a) the method
appears reproducible. The borderline between low and high
grade lymphomas determined by the percentage of Ki67
positive cells was found at about 25% in both studies.
Although the clinical follow-up period in this preliminary
prospective study is too limited to allow major conclusions,
we wish to draw attention to some cases in which a high
proliferation rate coincided with a more severe clinical
course than expected from the histological diagnosis. These
cases are identified.in Figure 2 and Table II: Myeloma, FCC
cb/cc foll 'D', FCC cb/cc diff 'E'. This discrepancy has also
been described in a previous study (Brittinger et al., 1981).
The reliable determination of cases with a poor outcome
very early could justify aggressive treatment in good
histological sub-types of NHL. Our preliminary data suggest
that the Mab Ki67 may provide a reliable tool for this
purpose but more long-term studies are needed to prove the
hypothesis.
We thank the Technical Staff of the University Department of
Pathology and Miss Julie T. Foster for preparation of the
manuscript.
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